Prostate Cancer Clinical Trial

PSMA-PET to Guide Prostatectomy

Summary

In this study, 288 patients will be randomized 1:1 to either having only the standard of care MRI prior to surgery versus having the standard of care MRI and the PSMA PET scan. PET (and MRI) findings will be validated against whole mount pathology. Pre-surgical imaging findings will also be evaluated in the context of affecting subsequent surgical plans and impacting actual patient outcomes.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Men diagnosed with prostate cancer who choose radical prostatectomy
Significant prostate cancer: Gleason 3+4 ≥1 core with pattern 4 ≥20% OR ≥3 cores of Gleason 3+4 OR Any Gleason 4+3, 4+4, 4+5, 5+4, or 5+5 AND
Baseline sexual function (IIEF-EF ≥ 17): No erectile dysfunction OR mild erectile dysfunction OR mild-to-moderate erectile dysfunction (International Index of Erectile Function-Erectile Function domain ≥ 17). AND
The patient desires to maintain erections following treatment.

Exclusion Criteria:

Participation in another investigational trial involving research exposure to ionizing radiation concurrently or within 30 days
Patient is unable to tolerate remaining still on the bed of the PET or MRI camera, due to physical limitations or claustrophobia.
c. Significant acute or chronic medical condition in the subject that could compromise the objectives of the study.

Study is for people with:

Prostate Cancer

Phase:

Phase 2

Estimated Enrollment:

288

Study ID:

NCT05381103

Recruitment Status:

Recruiting

Sponsor:

Five Eleven Pharma, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Goodman Hall, Indiana Institute for Biomedical Imaging Sciences, Indiana University School of Medicine
Indianapolis Indiana, 46202, United States More Info
Mark Green, Ph.D
Contact

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Phase:

Phase 2

Estimated Enrollment:

288

Study ID:

NCT05381103

Recruitment Status:

Recruiting

Sponsor:


Five Eleven Pharma, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.